Embargo
Item embargoed until 2026-09-02Document type
ArticleVersion
Accepted versionPublication date
All rights reserved
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/223052
Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited.
Journal Title
Director/Tutor
Journal ISSN
Volume Title
Related resource
Abstract
Anti-BCMA CAR-T cell therapy has revolutionized the prognosis of relapsed / refractory multiple myeloma patients. Regrettably, despite unprecedented overall response rates achieved with this approach, most patients eventually relapse. One of the primary reasons for this is the complete loss or reduced expression of BCMA on the malignant plasma cell surface. Consequently, new therapeutic targets are under investigation. Another potential therapeutic approach involves the use of CAR-T cells targeting two tumor antigens. In this study, we developed and validated a monospecific CAR targeting CD229, which was effective in in vitro and in vivo NSG mouse models with both homogeneous and heterogeneous BCMA expression. Additionally, we created a bicistronic CAR-T cell targeting both CD229 and BCMA, which demonstrated efficacy in models with homogeneous BCMA expression, in heterogeneous models featuring small clonal populations with biallelic BCMA deletion, and in cases with reduced BCMA expression both in vivo and in vitro. Regarding "on-target off-tumor toxicity," no fratricide was observed among CAR-T cells, but there was a limited elimination of non-activated T-cells. The immune pressure exerted by anti-CD229 CAR-T cells led to the loss of the CD229 antigen expression in some instances. In summary, this work underscores the potential utility of CD229 alone or in combination with BCMA, as an immunotherapeutic target in multiple myeloma, especially in cases marked by diminished or absent BCMA expression.
Subject
Subject (English)
Citation
Citation
RODRÍGUEZ LOBATO, Luis Gerardo, et al. Bicistronic CAR-T Cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited. Cancer Immunology Research. 2025. Vol. 13, num. 9, pags. 1374-1390. ISSN 2326-6074. [consulted: 6 of June of 2026]. Available at: https://hdl.handle.net/2445/223052